NCT00048724已完成3 期
PEG-Intron as Maintenance Therapy vs. an Untreated Control Group in Adult Subjects With Compensated Cirrhosis (METAVIR F4), Secondary to Chronic Hepatitis C, Who Have Failed to Respond to Therapy With Any Alpha Interferon Plus Ribavirin
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 631
- 主要终点
- Time to Observation of the First Clinical Event Experienced by a Subject
研究概览
简要总结
The objective of the study is to evaluate the safety and efficacy of PEG-Intron vs. no treatment for the prevention of disease progression in adult subjects with compensated cirrhosis secondary to chronic hepatitis C, who failed to respond to therapy with an a interferon plus ribavirin.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age at entry 18-65 years;
- •Non-responders to previous treatment (minimum of 3 months) with an alpha interferon plus ribavirin;
- •Liver biopsy demonstrating cirrhosis
排除标准
- •Any other cause for liver disease other than chronic hepatitis C;
- •History or presence of complications of cirrhosis;
- •Alcohol or illicit drug abuse or treatment with methadone within the past 2 years;
- •Diseases or conditions that could interfere with participation in the study
结局指标
主要结局
Time to Observation of the First Clinical Event Experienced by a Subject
时间窗: Up to 60 months of treatment or observation, or when 98 subjects experience at least one clinical event
Clinical events are liver decompensation \[variceal bleeding, development of Child-Pugh Class C, hepatic encephalopathy ≥Grade 2, ascites\], hepatic carcinoma, death, and/or liver transplantation
次要结局
- Time to Observation of the Disease Progression Experienced by a Subject(Up to 60 months of treatment or observation, or when 98 subjects experience at least one clinical event)
研究者
相似试验
已完成
3 期
Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)Chronic Hepatitis CLiver FibrosisNCT00049842Merck Sharp & Dohme LLC540
进行中（未招募）
1 期
A Study to Assess Treatment with PEG-Intron® and Rebetol® in Naïve Patients with Genotype 1 Chronic Hepatitis C and Slow Virological Response - Slow responder studyChronic Hepatitis C, Genotype 1EUCTR2004-000488-83-ESIntergrated Therapeutics Group, Incorporated-a subsidiary of Schering Plough1,200
进行中（未招募）
不适用
A Study to Assess Treatment with PEG-Intron® and Rebetol® in Naïve Patients with Genotype 1 Chronic Hepatitis C and Slow Virological Response - Slow responder studyEUCTR2004-000488-83-HUIntegrated Therapeutics Group, Incorporated-a subsidiary of Schering Plough1,200
进行中（未招募）
1 期
A Study to Assess Treatment with PEG-Intron® and Rebetol® in Naïve Patients with Genotype 1 Chronic Hepatitis C and Slow Virological Response - Slow responder studyEUCTR2004-000488-83-GBSchering Plough Research Institute, a Division of Schering Corporation1,200
进行中（未招募）
不适用
A Study to Assess Treatment with PEG-Intron® and Rebetol® in Naïve Patients with Genotype 1 Chronic Hepatitis C and Slow Virological Response - Slow responder studyChronic Hepatitis C, Genotype 1EUCTR2004-000488-83-CZIntergrated Therapeutics Group, Incorporated-a subsidiary of Schering Plough1,200